...
首页> 外文期刊>ACS nano >Uniformity of Drug Payload and Its Effect on Stability of Solid Lipid Nanoparticles Containing an Ester Prodrug
【24h】

Uniformity of Drug Payload and Its Effect on Stability of Solid Lipid Nanoparticles Containing an Ester Prodrug

机译:药物有效载荷的均匀性及其对含酯前药的固体脂质纳米颗粒稳定性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Nanocarrier systems are frequently characterized by their size distribution, while drug encapsulation in nanocarriers is generally characterized in terms of an entire population, assuming that drug distribution is uniform. Careful characterization of nanocarriers and assessment of their behavior in biological environments are essential for adequate prediction of the fate of the nanoparticles in vivo. Solid lipid nanoparticles containing [3H]-dexamethasone palmitate (an ester prodrug) and [14C]-stearyl alcohol (a component of the nanoparticle matrix) were prepared using the nanotemplate engineering method for bioresponsive tumor delivery to overcome interstitial fluid pressure gradients, a physiological barrier to tumor uptake of chemotherapeutic agents. While particle size analysis indicated a uniform size distribution of 93.2 ± 0.5 nm, gel filtration chromatography (GFC) revealed two nanoparticle populations. Drug encapsulation efficiency was 97%, but it distributed differently in the two populations, with average drug/lipid ratios of 0.04 and 0.25, respectively. The difference in surface properties resulted in distinguishing protein adsorption features of the two populations. GFC and HPLC profiles of the mixture of nanoparticles and human serum albumin (HSA) showed that no HSA was adsorbed to the first population of nanoparticles, but minor amounts were adsorbed to the second population. After 24 h incubation in 50% human plasma, ≥80% of the [3H]-dexamethasone palmitate was associated with nanoparticles. Thus, characterization of solid lipid nanoparticles produced by this method may be challenging from a regulatory perspective, but the strong association of the drug with the nanoparticles in plasma indicates that this nanocarrier system has the potential for in vivo application.
机译:纳米载体系统通常以其尺寸分布为特征,而假设药物分布是均匀的,则通常以整个人群来表征纳米载体中的药物包封。纳米载体的仔细表征及其在生物环境中的行为评估对于充分预测纳米粒子在体内的命运至关重要。使用纳米模板工程方法制备包含[3H]-地塞米松棕榈酸酯(酯类前药)和[14C]-硬脂醇(纳米颗粒基质的成分)的固体脂质纳米颗粒,用于生物响应性肿瘤递送,以克服组织间液压力梯度,一种生理学肿瘤吸收化疗药物的障碍。粒度分析显示均匀的大小分布为93.2±0.5 nm,而凝胶过滤色谱(GFC)显示了两个纳米粒子种群。药物封装效率为97%,但在两个人群中的分布不同,平均药物/脂质比率分别为0.04和0.25。表面性质的差异导致两个群体的蛋白质吸附特征不同。纳米颗粒和人血清白蛋白(HSA)混合物的GFC和HPLC谱图表明,第一类纳米颗粒没有吸附任何HSA,而第二种纳米颗粒则吸附了少量。在50%人体血浆中孵育24小时后,≥80%的[3H]-地塞米松棕榈酸酯与纳米颗粒相关。因此,从监管的角度来看,用这种方法生产的固体脂质纳米颗粒的表征可能具有挑战性,但是药物与血浆中的纳米颗粒的强结合表明该纳米载体系统具有体内应用的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号